GlassScriptPhysician profile
Tony N Heiar
NPI 1538316534
$1,810.27
in general payments reported to CMS, 2019-2025
34 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.78 · 2022: $84.21 · 2023: $212 · 2024: $480 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352 · Education: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.10 |
| Education | $348.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $229.45 | 2024-2025 | Erleada, Darzalex, Talvey |
| Seagen INC. | $198.99 | 2023 | |
| Abbvie INC. | $175.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $147.80 | 2024-2025 | Tagrisso, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $116.23 | 2022-2025 | |
| Pfizer INC. | $67.55 | 2024-2025 | |
| Beigene USA, INC. | $60.20 | 2024-2025 | Tevimbra |
| Lilly USA, LLC | $58.96 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $54.54 | 2025 | |
| Genentech USA, INC. | $54.19 | 2024-2025 | Polivy, Columvi, Gazyva |
| Daiichi Sankyo INC. | $47.52 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $46.65 | 2024-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $41.43 | 2024 | Opdivo, Krazati |
| Exelixis INC. | $41.20 | 2024 | |
| Genzyme Corporation | $40.46 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.99 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $32.32 | 2022 | |
| Eisai INC. | $27.16 | 2025 | |
| Karyopharm Therapeutics INC. | $26.43 | 2025 | Xpovio |
| Biohaven Pharmaceuticals, INC. | $25.78 | 2021 | |
| Servier Pharmaceuticals LLC | $24.31 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.31 | 2025 | Ultomiris |
| Celgene Corporation | $22.11 | 2025 | Breyanzi |
| Tersera Therapeutics LLC | $20.74 | 2025 | Zoladex |
| Stemline Therapeutics INC. | $20.30 | 2025 | Orserdu |
| Beone Medicines USA, INC. | $18.05 | 2025 | Brukinsa |
| Sobi, INC | $17.92 | 2024 | |
| Pharmaessentia USA Corporation | $17.91 | 2025 | Besremi |
| Astellas Pharma US INC | $17.54 | 2025 | Padcev |
| Glaxosmithkline, LLC. | $16.63 | 2024 | Jemperli, Zejula |
| Taiho Oncology, INC. | $15.67 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.59 | 2025 | Iclusig |
| Recordati_rare_diseases_inc. | $14.74 | 2025 | Enjaymo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Heiar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.